Miraluma
DRUG DESCRIPTION
MIRALUMA®
Kit for the Preparation of Technetium Tc99m Sestamibi for Injection
FOR DIAGNOSTIC USE
DESCRIPTION
Each 5 mL vial contains a sterile, non-pyrogenic, lyophilized mixture of:
Tetrakis (2-methoxy isobutyl isonitrile) Copper (I) tetrafluoroborate - 1.0 mg Sodium Citrate Dihydrate - 2.6 mg L-Cysteine Hydrochloride Monohydrate - 1.0 mg Mannitol - 20 mg Stannous Chloride, Dihydrate, minimum (SnCl22H2O) - 0.025 mg Stannous Chloride, Dihydrate, (SnCl22H2O) - 0.075 mg
Tin Chloride (stannous and stannic) Dihydrate, maximum (as SnCl22H2O) - 0.086 mg
Prior to lyophilization the pH is 5.3 to 5.9. The contents of the vial are lyophilized and stored under nitrogen.
This drug is administered by intravenous injection for diagnostic use after reconstitution with sterile, non-pyrogenic, oxidant-free Sodium Pertechnetate Tc99m Injection. The pH of the reconstituted product is 5.5 (5.0 - 6.0). No bacteriostatic preservative is present.
The precise structure of the technetium complex is Tc99m[MIBI]6+ where MIBI is 2-methoxy isobutyl isonitrile.
PHYSICAL CHARACTERISTICS
Technetium Tc99m decays by isomeric transition with a physical half-life of 6.02 hours1. Photons that are useful for detection and imaging studies are listed in Table 1.
| Table 1. Principle Radiation Emission Data | ||
| Radiation | Mean %/Disintegration | Mean Energy (KeV) |
| Gamma -2 | 89.07 | 140.5 |
| 1Kocher, David, C., Radioactive Decay Data Tables, DOE/TIC-11026, 108(1981). | ||
EXTERNAL RADIATION
The specific gamma ray constant for Tc99m is 5.4 microcoulombs/Kg-MBq-hr (0.78R/mCi-hr) at 1 cm. The first half value layer is 0.017 cm of Pb. A range of values for the relative attenuation of the radiation emitted by this radionuclide that results from interposition of various thicknesses of Pb is shown in Table 2. To facilitate control of the radiation exposure from Megabequerel (millicurie) amounts of this radionuclide, the use of a 0.25 cm thickness of Pb will attenuate the radiation emitted by a factor of 1,000.
| Table 2. Radiation Attenuation by Lead Shielding | |
| Shield Thickness (Pb) cm | Coefficient of Attenuation |
| 0.017 | 0.5 |
| 0.08 | 10-1 |
| 0.16 | 10-2 |
| 0.25 | 10-3 |
| 0.33 | 10-4 |
To correct for physical decay of this radionuclide, the fractions that remain at selected intervals after the time of calibration are shown in Table 3.
| Table 3. Physical Decay Chart; Tc99m Half-Life 6.02 Hours | |||
| Hours | Fraction Remaining | Hours | Fraction Remaining |
| 0* | 1.000 | 8 | .398 |
| 1 | .891 | 9 | .355 |
| 2 | .794 | 10 | .316 |
| 3 | .708 | 11 | .282 |
| 4 | .631 | 12 | .251 |
| 5 | .562 | ||
| 6 | .501 | ||
| 7 | .447 | ||
| *Calibration Time | |||
Generic Name: Technetium Tc99m sestamibi
Women's Health
Find out what women really need.
3D Mammogram
Learn how new technology may change the way breast cancer is diagnosed and in turn, save more lives. See more WebMD Videos »
ENABLEX is a prescription medicine used in adults to treat the following symptoms due to a condition called overactive bladder:
- · having a strong need to go to the bathroom right away (also called "urgency")
- · leaks or wetting accidents (also called "urinary incontinence")
- · having to go to the bathroom too often (also called "urinary frequency")
IMPORTANT SAFETY INFORMATION
You should not take once-daily ENABLEX if you have certain types of stomach problems, glaucoma, or have trouble emptying your bladder. Side effects of ENBLEX include blurred vision, and more commonly dry mouth, constipation, indigestion, and abdominal pain. Use caution when doing certain activities until you know how ENBALEX affects you.

